RxDoctor Payments Data

Sreevalli Pariti, MD

Nephrology · Dallas, TXNPI 1275722233

Payments from drug & device makers

$3,415in general payments, 2019–2025

Across 154 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$299
  • Travere Therapeutics, Inc.$211
  • GSK$144
  • Otsuka America Pharmaceutical, Inc.$89
  • Aurinia Pharma U.S., Inc.$88
  • plus $667 from 16 others

What the payments were for

  • Food & beverage$3,414100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,415 in reported general payments places this provider in the 60th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$144,776
Medicare patients
170
Services billed
1,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide21$58,448
FarxigaDapagliflozin Propanediol45$29,448
Sevelamer Carbonate45$10,752
LokelmaSodium Zirconium Cyclosilicate13$10,311
JardianceEmpagliflozin14$8,696
Calcium Acetate15$1,689
Torsemide47$1,053
Nifedipine ErNifedipine41$818
Amlodipine Besylate85$382
Lisinopril31$297
Losartan Potassium44$261
Calcitriol14$226
Carvedilol29$174
Hydralazine Hcl16$173
Atorvastatin Calcium24$150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$38$58,44821 claims
AstraZenecaFarxiga, Lokelma$1,917$39,75858 claims
Boehringer IngelheimJardiance$76$8,69614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →